Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 7/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.31 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9805805 | 1.00 | GRIK1 (0.34) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL2476549 | 0.87 | CA2 (0.40) | GRIK1 | |
| SCHEMBL2476548 | 0.87 | CA2 (0.40) | GRIK1 | |
| SCHEMBL25698 | 0.80 | GRIK1 (0.38) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL25697 | 0.80 | GRIK1 (0.38) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL10361829 | 0.77 | GRIK1 (0.54) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL143410 | 0.77 | — | — | |
| SCHEMBL143409 | 0.77 | — | — | |
| SCHEMBL716220 | 0.74 | GRIK1 (0.33) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL716221 | 0.74 | GRIK1 (0.33) | GRIK1GRIK2GRIA2GRIA4GRIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0269598-B1 | THERAPEUTICAL AGENTS AGAINST LEISHMANIOSE | N.V. SOPAR S.A. (BE) | 1991-04-10 | — | — | EP | claimed |
| CN-113840594-A | Poly (alkyl cyanoacrylate) nanoparticles for the treatment of cancer | 新泰福托特股份有限公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-111989087-A | Poly (alkyl cyanoacrylate) nanoparticles for the treatment of cancer | 新泰福托特股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| WO-2017046037-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION AND THEIR USES | ONXEO (FR) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071866-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION, AND THEIR USES | ONXEO S.A. (FR) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071866-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION, AND THEIR USES | MPO, EXOSC9, CD63 | GRIK1 4608/4885GRIK2 4622/4885GRIA2 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.